<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082779</url>
  </required_header>
  <id_info>
    <org_study_id>CS0159-001</org_study_id>
    <nct_id>NCT05082779</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Contralled, Single Asending Dose / Multiple Ascending Dose Study of CS0159 to to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Effect Food in Healthy Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascade Pharmaceuticals, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cascade Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The whole study includes 2 parts. Both the SAD study and MAD study are randomized,&#xD;
      double-blinded, and placebo-controlled studies, conducted in healthy subjects, to assess the&#xD;
      safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of CS0159. The SAD part&#xD;
      also involves a pilot food effect (FE) study, designed to assess the food effect on&#xD;
      single-dose PK profile in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 48 healthy subjects will be allocated to 1 of 6 cohorts (cohort A1~A6) in the SAD&#xD;
      study, each cohort including 8 subjects (6 subjects will receive investigational new drug&#xD;
      (IND) product and 2 receive placebo). Each subject in fasted state will be randomly assigned&#xD;
      to receive a single oral dose of CS0159 or placebo.To ensure the safety for all SAD cohorts&#xD;
      (including A3 in both treatment periods).&#xD;
&#xD;
      The MAD study will enroll 32 healthy subjects, allocated to 1 of 4 cohorts (cohort B1~B4) and&#xD;
      each cohort including 8 participants (6 subjects will receive IND products and 2 receive&#xD;
      placebo). Subjects will be randomly assigned to orally receive the IND product or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 26, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-Dose Pharmacokinetic (PK) Parameter</measure>
    <time_frame>Day 1 after dosing</time_frame>
    <description>Area under the concentration-time curve (AUC) from time zero to infinity (AUC0-âˆž)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-Dose Pharmacokinetic (PK) Parameter: (AUC0-last)</measure>
    <time_frame>Day 1 after dosing</time_frame>
    <description>AUC from time zero to the time of the last measured concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-Dose Pharmacokinetic (PK) Parameter: (Cmax)</measure>
    <time_frame>Day 1 after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-Dose Pharmacokinetic (PK) Parameter: (Tmax)</measure>
    <time_frame>Day 1 after dosing</time_frame>
    <description>Time of the maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-Dose PK Parameter</measure>
    <time_frame>Day 1 after dosing; day 14</time_frame>
    <description>Maximum concentration during a dosing interval Ct_max</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-Dose PK Parameter: (Ct_min, Day 14)</measure>
    <time_frame>Day 1 after dosing; day 14</time_frame>
    <description>Minimum concentration during a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-Dose PK Parameter: (AUCtau)</measure>
    <time_frame>Day 1 after dosing; day 14</time_frame>
    <description>AUC over one dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the safety and tolerability of single dose of CS0159</measure>
    <time_frame>up to Day 31</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the safety and tolerability of multiple doses of CS0159</measure>
    <time_frame>up to Day 44</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameter: FGF19</measure>
    <time_frame>Day -1; day 1</time_frame>
    <description>fibroblast growth factor 19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Parameter: C4</measure>
    <time_frame>Day -1; day 1</time_frame>
    <description>serum concentration</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Primary Sclerosing Cholangitis (PSC)</condition>
  <arm_group>
    <arm_group_label>Cohort A1: 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 0.2 mg or placebo once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 0.6 mg or placebo once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 1 mg or placebo once on Day 1 followed by a 7-day washout period then given in 1 mg tablet (in fed state) on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 2 mg or placebo once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5: 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 4 mg or placebo once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A6: 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 8 mg or placebo once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1: 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 0.4 mg or placebo once daily for a consecutive 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2: 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 1 mg or placebo once daily for a consecutive 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3: 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 2 mg or placebo once daily for a consecutive 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B4: 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in fasted state will receive CS0159 4 mg or placebo once daily for a consecutive 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS0159</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Cohort A1: 0.2 mg</arm_group_label>
    <arm_group_label>Cohort A2: 0.6 mg</arm_group_label>
    <arm_group_label>Cohort A3: 1 mg</arm_group_label>
    <arm_group_label>Cohort A4: 2 mg</arm_group_label>
    <arm_group_label>Cohort A5: 4 mg</arm_group_label>
    <arm_group_label>Cohort A6: 8 mg</arm_group_label>
    <arm_group_label>Cohort B1: 0.4 mg</arm_group_label>
    <arm_group_label>Cohort B2: 1 mg</arm_group_label>
    <arm_group_label>Cohort B3: 2 mg</arm_group_label>
    <arm_group_label>Cohort B4: 4mg</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and non-pregnant female volunteers&#xD;
&#xD;
          2. In good health, determined by having no clinically significant findings from medical&#xD;
             history, physical examination, 12-lead ECG, vital signs measurements, and clinical&#xD;
             laboratory evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with special dietary requirements and cannot follow a uniform diet.&#xD;
&#xD;
          2. Pregnant or nursing females or females who have pregnancy plans during the trial or&#xD;
             within 3 months after the trial.&#xD;
&#xD;
          3. Any subject with SARS-CoV-2 infection, based on a positive polymerase chain reaction&#xD;
             for SARS-CoV-2.&#xD;
&#xD;
          4. History or evidence of clinically significant disorder, condition, or disease that, in&#xD;
             the opinion of the investigator, would pose a risk to subject safety or interfere with&#xD;
             the study evaluations, procedures, or completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Doisy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Labcorp Clinical Research Unit, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Labcorp Clinical Research Unit, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathleen Doisy, MD</last_name>
      <phone>386-366-6427</phone>
      <email>Kathleen.Doisy@covance.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

